HRP20151018T1 - Pirolopiridini kao inhibitori kinaze - Google Patents

Pirolopiridini kao inhibitori kinaze Download PDF

Info

Publication number
HRP20151018T1
HRP20151018T1 HRP20151018TT HRP20151018T HRP20151018T1 HR P20151018 T1 HRP20151018 T1 HR P20151018T1 HR P20151018T T HRP20151018T T HR P20151018TT HR P20151018 T HRP20151018 T HR P20151018T HR P20151018 T1 HRP20151018 T1 HR P20151018T1
Authority
HR
Croatia
Prior art keywords
image
alkyl
hydrogen
compound according
pharmaceutically acceptable
Prior art date
Application number
HRP20151018TT
Other languages
English (en)
Croatian (hr)
Inventor
Yvan Le Huerou
James F. Blake
Indrani W. Gunwardana
Peter J. Mohr
Eli M. Wallace
Bin Wang
Mark Chicarelli
Michael Lyon
Original Assignee
Array Biopharma, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40810786&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20151018(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Array Biopharma, Inc. filed Critical Array Biopharma, Inc.
Publication of HRP20151018T1 publication Critical patent/HRP20151018T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HRP20151018TT 2008-05-13 2009-05-13 Pirolopiridini kao inhibitori kinaze HRP20151018T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5292608P 2008-05-13 2008-05-13
PCT/US2009/043691 WO2009140320A1 (en) 2008-05-13 2009-05-13 Pyrrolopyridines as kinase inhibitors
EP09747404.3A EP2307409B1 (en) 2008-05-13 2009-05-13 Pyrrolopyridines as kinase inhibitors

Publications (1)

Publication Number Publication Date
HRP20151018T1 true HRP20151018T1 (hr) 2015-10-23

Family

ID=40810786

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20151018TT HRP20151018T1 (hr) 2008-05-13 2009-05-13 Pirolopiridini kao inhibitori kinaze

Country Status (30)

Country Link
US (6) US8178131B2 (https=)
EP (2) EP2307409B1 (https=)
JP (2) JP5703212B2 (https=)
KR (2) KR101657856B1 (https=)
CN (3) CN102089307B (https=)
AR (1) AR071717A1 (https=)
AU (1) AU2009246402B2 (https=)
BR (1) BRPI0913580B8 (https=)
CA (1) CA2724262C (https=)
CL (1) CL2009001152A1 (https=)
CO (1) CO6321244A2 (https=)
CR (1) CR11803A (https=)
CY (1) CY1116692T1 (https=)
DK (1) DK2307409T3 (https=)
ES (1) ES2552643T3 (https=)
HK (1) HK1219950A1 (https=)
HR (1) HRP20151018T1 (https=)
HU (1) HUE026160T2 (https=)
IL (1) IL209258A (https=)
MX (1) MX2010012449A (https=)
NZ (1) NZ589318A (https=)
PH (1) PH12013501779B1 (https=)
PL (1) PL2307409T3 (https=)
PT (1) PT2307409E (https=)
RS (1) RS54358B1 (https=)
RU (1) RU2517194C2 (https=)
SI (1) SI2307409T1 (https=)
TW (2) TWI458727B (https=)
UA (1) UA111933C2 (https=)
WO (1) WO2009140320A1 (https=)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8841304B2 (en) 2008-01-08 2014-09-23 Array Biopharma, Inc. Pyrrolopyridines as kinase inhibitors
CN101965347B (zh) 2008-01-09 2013-01-02 阵列生物制药公司 作为激酶抑制剂的吡唑并吡啶
JP2009256298A (ja) * 2008-03-26 2009-11-05 Sumitomo Chemical Co Ltd ピペリジン−３−イルカーバメート化合物の光学分割方法およびその中間体
AR071717A1 (es) 2008-05-13 2010-07-07 Array Biopharma Inc Pirrolo[2,3-b]piridinas inhibidoras de quinasas chk1 y chk2,composiciones farmaceuticas que las contienen,proceso para prepararlas y uso de las mismas en el tratamiento y prevencion del cancer.
US8481557B2 (en) 2009-04-11 2013-07-09 Array Biopharma Inc. Method of treatment using checkpoint kinase 1 inhibitors
SG10201404012RA (en) * 2009-04-11 2014-09-26 Array Biopharma Inc Checkpoint kinase 1 inhibitors for potentiating dna damaging agents
TWI466885B (zh) 2009-07-31 2015-01-01 Japan Tobacco Inc 含氮螺環化合物及其醫藥用途
US9029359B2 (en) * 2009-09-04 2015-05-12 Biogen Idec Ma, Inc. Heteroaryl Btk inhibitors
EP2606051B1 (en) 2010-08-20 2016-10-05 Hutchison Medipharma Limited Pyrrolopyrimidine compounds and uses thereof
ES2621857T3 (es) * 2010-11-16 2017-07-05 Array Biopharma, Inc. Combinación de inhibidores de la cinasa 1 de punto de control e inhibidores de la cinasa WEE1
PL2678329T3 (pl) 2011-02-25 2016-06-30 Array Biopharma Inc Związki triazolopirydyny jako inhibitory kinaz pim
JP2014516941A (ja) 2011-04-29 2014-07-17 アムジェン インコーポレイテッド Ｐｉｍ阻害剤としての二環式ピリダジン化合物
GB201201566D0 (en) * 2012-01-30 2012-03-14 Vernalis R&D Ltd New chemical compounds
AR090789A1 (es) * 2012-04-23 2014-12-10 Genentech Inc Intermediarios y procesos para la preparacion de compuestos
CN105764501A (zh) 2013-07-26 2016-07-13 现代化制药公司 改善比生群治疗效益的组合物
WO2015027090A1 (en) * 2013-08-22 2015-02-26 Genentech, Inc. Intermediates and processes for preparing compounds
KR102325163B1 (ko) * 2013-08-22 2021-11-11 제넨테크, 인크. 화합물의 제조 방법
SG10201802061TA (en) 2013-09-25 2018-05-30 Vertex Pharma A selective inhibitor of phosphatidylinositol 3-kinase-gamma
KR102359214B1 (ko) 2014-04-04 2022-02-07 델 마 파마슈티컬스 폐의 비소세포 암종 및 난소암을 치료하기 위한 디안하이드로갈락티톨 및 이의 유사체 또는 유도체
TW201613919A (en) 2014-07-02 2016-04-16 Pharmacyclics Llc Inhibitors of Bruton's tyrosine kinase
MA41599A (fr) 2015-02-26 2018-01-02 Array Biopharma Inc Formes cristallines d'un composé pyrrolopyridine
WO2017003090A1 (ko) 2015-06-30 2017-01-05 서울바이오시스 주식회사 Uv led가 적용된 포충기
PL3371165T3 (pl) * 2015-11-04 2022-05-02 Merck Patent Gmbh Inhibitor btk do zastosowania w terapii rakowej
AU2016378579A1 (en) * 2015-12-22 2018-06-14 Vitae Pharmaceuticals, Inc. Inhibitors of the menin-MLL interaction
EP3805215A1 (en) 2016-06-10 2021-04-14 Vitae Pharmaceuticals, LLC Inhibitors of the menin-mll interaction
EP3461480A1 (en) 2017-09-27 2019-04-03 Onxeo Combination of a dna damage response cell cycle checkpoint inhibitors and belinostat for treating cancer
US12448374B2 (en) 2018-06-07 2025-10-21 Disarm Therapeutics, Inc. Inhibitors of SARM1
CN112823036B (zh) * 2018-07-03 2024-11-08 艾福姆德尤股份有限公司 用于治疗与sting活性有关的疾病的化合物和组合物
CN109053526A (zh) * 2018-08-13 2018-12-21 南通大学 一种（3r，4s）-4-甲基吡咯烷-3-基氨基甲酸叔丁酯盐酸盐的化学合成方法
CN108912032A (zh) * 2018-08-13 2018-11-30 南通大学 一种（3s，4r）-4-甲基吡咯烷-3-基氨基甲醇叔丁酯盐酸盐的化学合成方法
WO2020132045A1 (en) 2018-12-19 2020-06-25 Disarm Therapeutics, Inc. Inhibitors of sarm1 in combination with neuroprotective agents
TW202043198A (zh) 2019-01-17 2020-12-01 美商Ｉｆｍ Ｄｕｅ有限公司 用於治療與sting活性相關之病況的化合物及組合物
MX2022012471A (es) 2020-04-07 2022-11-30 Syndax Pharmaceuticals Inc Combinaciones de inhibidores de menina e inhibidores de cyp3a4 y métodos de uso de las mismas.
EP4182310A1 (en) 2020-07-15 2023-05-24 IFM Due, Inc. Compounds and compositions for treating conditions associated with sting activity
TW202235073A (zh) 2021-01-08 2022-09-16 美商Ｉｆｍ Ｄｕｅ有限公司 用於治療與sting活性相關的病狀之化合物及組合物
TW202311262A (zh) 2021-05-14 2023-03-16 美商錫達斯醫藥股份有限公司 Menin-mll交互作用之抑制劑
UY39892A (es) 2021-08-10 2023-03-31 Novartis Pharma Ag Compuestos y composiciones para tratar afecciones asociadas con la actividad de STING
CN119798252A (zh) * 2023-10-09 2025-04-11 中国石油化工股份有限公司 一种制备n邻位-酰基取代的含氮杂环化合物及其缩胺合铁(ii)配合物的方法
WO2025260014A1 (en) * 2024-06-14 2025-12-18 Tenvie Therapeutics, Inc. Compounds, compositions, and methods
WO2025261366A1 (zh) * 2024-06-18 2025-12-26 南京正大天晴制药有限公司 一种五元并六元杂环化合物及用途

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR960704887A (ko) * 1993-10-14 1996-10-09 챨스 엠. 브록 퀴놀리지논형 화합물 (Quinolizinone type compounds)
US5543523A (en) 1994-11-15 1996-08-06 Regents Of The University Of Minnesota Method and intermediates for the synthesis of korupensamines
WO2001058869A2 (en) 2000-02-11 2001-08-16 Bristol-Myers Squibb Company Cannabinoid receptor modulators, their processes of preparation, and use of cannabinoid receptor modulators in treating respiratory and non-respiratory diseases
JP2004501083A (ja) 2000-04-18 2004-01-15 アゴーロン・ファーマシューティカルズ・インコーポレイテッド プロテインキナーゼを阻害するためのピラゾール
AU2002336462A1 (en) 2001-09-06 2003-03-24 Millennium Pharmaceuticals, Inc. Piperazine and homopiperazine compounds
WO2003028724A1 (en) 2001-10-04 2003-04-10 Smithkline Beecham Corporation Chk1 kinase inhibitors
US6797825B2 (en) 2001-12-13 2004-09-28 Abbott Laboratories Protein kinase inhibitors
TWI329112B (en) 2002-07-19 2010-08-21 Bristol Myers Squibb Co Novel inhibitors of kinases
BR0313262A (pt) 2002-08-07 2005-07-12 Mitsubishi Pharma Corp Compostos de dihidropirazolpiridina
US20050256157A1 (en) 2002-08-23 2005-11-17 Chiron Corporation Combination therapy with CHK1 inhibitors
US8580782B2 (en) 2002-09-04 2013-11-12 Merck Sharp & Dohme Corp. Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors
AR042667A1 (es) 2002-12-26 2005-06-29 Taisho Pharmaceutical Co Ltd Derivados de pirrolopirimidina y pirrolopiridina sustituidos con un grupo amino ciclico
AU2004220176A1 (en) 2003-03-14 2004-09-23 Astrazeneca Ab Novel fused triazolones and the uses thereof
GB0308208D0 (en) * 2003-04-09 2003-05-14 Glaxo Group Ltd Chemical compounds
GB0330043D0 (en) * 2003-12-24 2004-01-28 Pharmacia Italia Spa Pyrrolo [2,3-b] pyridine derivatives active as kinase inhibitors process for their preparation and pharmaceutical compositions comprising them
GB0330042D0 (en) * 2003-12-24 2004-01-28 Pharmacia Italia Spa Pyrrolo [2,3-b] pyridine derivatives active as kinase inhibitors process for their preparation and pharmaceutical compositions them
KR20070002081A (ko) * 2004-04-02 2007-01-04 버텍스 파마슈티칼스 인코포레이티드 Ｒｏｃｋ 및 기타 단백질 키나아제의 억제제로서 유용한아자인돌
JP4926943B2 (ja) * 2004-04-13 2012-05-09 シンタ ファーマシューティカルズ コーポレーション Ｉｌ−１２産生を阻害する二塩
GB0409080D0 (en) 2004-04-23 2004-05-26 Biofocus Discovery Ltd Compounds which interact with protein kinases
JP2007161585A (ja) 2004-06-25 2007-06-28 Taisho Pharmaceut Co Ltd 環状アミノ基で置換されているピロロピリミジン及びピロロピリジン誘導体
UY29177A1 (es) * 2004-10-25 2006-05-31 Astex Therapeutics Ltd Derivados sustituidos de purina, purinona y deazapurina, composiciones que los contienen métodos para su preparación y sus usos
GB0501999D0 (en) 2005-02-01 2005-03-09 Sentinel Oncology Ltd Pharmaceutical compounds
JP2008534664A (ja) 2005-04-06 2008-08-28 アストラゼネカ アクチボラグ 置換複素環およびｃｈｋ１、ｐｄｋ１及びｐａｋ阻害剤としてのそれらの使用
WO2006127587A1 (en) 2005-05-20 2006-11-30 Vertex Pharmaceuticals Incorporated Pyrrolopyridines useful as inhibitors of protein kinase
KR101149954B1 (ko) * 2005-08-30 2012-06-01 아사히 가세이 파마 가부시키가이샤 술폰아미드 화합물
CN101321760A (zh) 2005-10-06 2008-12-10 先灵公司 作为蛋白激酶抑制剂的吡唑并嘧啶
US20070082900A1 (en) 2005-10-06 2007-04-12 Schering Corporation Methods for inhibiting protein kinases
EP2455382B1 (en) 2005-12-13 2016-10-26 Incyte Holdings Corporation Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors
US20070208053A1 (en) 2006-01-19 2007-09-06 Arnold Lee D Fused heterobicyclic kinase inhibitors
DE102006005180A1 (de) 2006-02-06 2007-08-09 Merck Patent Gmbh Indazol-heteroaryl-derivate
DE102006005179A1 (de) 2006-02-06 2007-08-09 Merck Patent Gmbh Aminoindazolderivate
WO2007125321A2 (en) 2006-04-25 2007-11-08 Astex Therapeutics Limited Purine and deazapurine derivatives as pharmaceutical compounds
EP2037931A2 (en) 2006-04-25 2009-03-25 Astex Therapeutics Limited Pharmaceutical combinations of pk inhibitors and other active agents
WO2007125315A2 (en) 2006-04-25 2007-11-08 Astex Therapeutics Limited Pharmaceutical compounds
WO2008012635A2 (en) * 2006-07-26 2008-01-31 Pfizer Products Inc. Amine derivatives useful as anticancer agents
WO2008075007A1 (en) 2006-12-21 2008-06-26 Cancer Research Technology Limited Morpholino-substituted bicycloheteroaryl compounds and their use as anti cancer agents
MX2009009304A (es) 2007-03-01 2009-11-18 Novartis Ag Inhibidores de cinasa pim y metodos para su uso.
EP2170886A1 (en) 2007-07-02 2010-04-07 Cancer Research Technology Limited 9h-pyrimido[4,5-b]indoles, 9h-pyrido[4',3':4,5]pyrrolo[2,3-d]pyridines, and 9h-1,3,6,9-tetraaza-fluorenes as chk1 kinase function inhibitors
JP2011503084A (ja) 2007-11-07 2011-01-27 シェーリング コーポレイション 新規の細胞周期チェックポイント調節剤およびこれらの調節剤とチェックポイント阻害剤との併用
US8841304B2 (en) 2008-01-08 2014-09-23 Array Biopharma, Inc. Pyrrolopyridines as kinase inhibitors
CN101965347B (zh) 2008-01-09 2013-01-02 阵列生物制药公司 作为激酶抑制剂的吡唑并吡啶
AR071717A1 (es) 2008-05-13 2010-07-07 Array Biopharma Inc Pirrolo[2,3-b]piridinas inhibidoras de quinasas chk1 y chk2,composiciones farmaceuticas que las contienen,proceso para prepararlas y uso de las mismas en el tratamiento y prevencion del cancer.
US8481557B2 (en) * 2009-04-11 2013-07-09 Array Biopharma Inc. Method of treatment using checkpoint kinase 1 inhibitors
US20140221370A1 (en) 2010-07-09 2014-08-07 Array Biopharma Inc. Pyrrolopyridines as kinase inhibitors
ES2621857T3 (es) 2010-11-16 2017-07-05 Array Biopharma, Inc. Combinación de inhibidores de la cinasa 1 de punto de control e inhibidores de la cinasa WEE1

Also Published As

Publication number Publication date
CN102089307A (zh) 2011-06-08
KR20140093266A (ko) 2014-07-25
CO6321244A2 (es) 2011-09-20
PH12013501779B1 (en) 2019-02-13
UA111933C2 (uk) 2016-07-11
EP2990407B1 (en) 2019-10-16
US9365568B2 (en) 2016-06-14
RU2010150786A (ru) 2012-06-20
TWI554512B (zh) 2016-10-21
AR071717A1 (es) 2010-07-07
US20160368916A1 (en) 2016-12-22
US20140243520A1 (en) 2014-08-28
EP2307409B1 (en) 2015-08-12
US20110070317A1 (en) 2011-03-24
CN104926810B (zh) 2019-02-19
CR11803A (es) 2011-02-11
RU2517194C2 (ru) 2014-05-27
AU2009246402B2 (en) 2013-05-23
TW201529573A (zh) 2015-08-01
HK1152035A1 (en) 2012-02-17
IL209258A0 (en) 2011-01-31
CA2724262A1 (en) 2009-11-19
US20130045286A1 (en) 2013-02-21
BRPI0913580A2 (pt) 2015-10-20
BRPI0913580B8 (pt) 2021-05-25
KR20110008102A (ko) 2011-01-25
US8178131B2 (en) 2012-05-15
KR101643426B1 (ko) 2016-07-27
TWI458727B (zh) 2014-11-01
US8545897B2 (en) 2013-10-01
HK1219950A1 (en) 2017-04-21
US8758830B2 (en) 2014-06-24
IL209258A (en) 2017-01-31
MX2010012449A (es) 2011-05-25
DK2307409T3 (en) 2015-09-21
US9969727B2 (en) 2018-05-15
CN102089307B (zh) 2015-07-01
KR101657856B1 (ko) 2016-09-19
WO2009140320A1 (en) 2009-11-19
PT2307409E (pt) 2015-11-04
PL2307409T3 (pl) 2016-01-29
JP5703212B2 (ja) 2015-04-15
BRPI0913580B1 (pt) 2020-03-10
CY1116692T1 (el) 2017-03-15
HUE026160T2 (en) 2016-05-30
US20140100369A1 (en) 2014-04-10
CN109942575A (zh) 2019-06-28
JP2015098482A (ja) 2015-05-28
RS54358B1 (sr) 2016-04-28
CL2009001152A1 (es) 2009-10-16
US8981085B2 (en) 2015-03-17
NZ589318A (en) 2011-06-30
US20150322061A1 (en) 2015-11-12
PH12013501779A1 (en) 2014-08-27
CN104926810A (zh) 2015-09-23
EP2990407A1 (en) 2016-03-02
TW201002707A (en) 2010-01-16
AU2009246402A1 (en) 2009-11-19
CA2724262C (en) 2017-08-15
SI2307409T1 (sl) 2015-11-30
ES2552643T3 (es) 2015-12-01
JP2011520896A (ja) 2011-07-21
EP2307409A1 (en) 2011-04-13

Similar Documents

Publication Publication Date Title
HRP20151018T1 (hr) Pirolopiridini kao inhibitori kinaze
RU2011107437A (ru) Ингибиторы кинуренин-3-моноксигеназы
HRP20201469T1 (hr) Derivati tetrahidroizokinolina
JP2021502356A5 (https=)
JP2012525395A5 (https=)
JP2016523911A5 (https=)
JP2018512381A5 (https=)
JP2016500073A5 (https=)
RU2016102137A (ru) Первичные карбоксамиды в качестве ингибиторов bik
RU2009140149A (ru) Пиримидингидразидные соединения как ингибиторы pgds
HRP20160635T1 (hr) Inhibitori pirimidina pde10
HRP20181017T1 (hr) Heterociklični spojevi i postupci uporabe
RU2010130175A (ru) Производные бензотиазола и бензоксазола и способы их применения
NZ630467A (en) Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith
JP2017528519A5 (https=)
ME01290B (me) Piradizinski derivati kao smo inhibitori
JP2016145215A5 (https=)
WO2016027195A1 (en) Aminopyrimidinyl compounds as jak inhibitors
RU2011137399A (ru) Гетероциклическое производное
HRP20200098T1 (hr) Spirociklični spojevi kao inhibitori triptofan hidroksilaze
AR104447A1 (es) Azabenzimidazoles y sus usos como moduladores de los receptores ampa
RU2015111133A (ru) Ингибиторы тирозинкиназы брутона
CA2637658A1 (en) Aurora kinase modulators and method of use
HRP20201430T1 (hr) Spojevi 6-heterociklil-4-morfolin-4-ilpiridin-2-ona korisni za liječenje karcinoma i dijabetesa
JP2016523976A5 (https=)